AGL
Agilon Health, Inc.
AGL lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AGL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Unavailable |
AGL's revenue and profitability are currently stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AGL PE Valuation
AGL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 59x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AGL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
AGL has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.86 | — |
| Q3 2026 | -$5.46 | +$13.21 |
| Q2 2026 | -$14.08 | +$5.09 |
| Q1 2026 | -$21.43 | -$6.70 |
| Q4 2025 | -$23.63 | -$7.80 |
| Q3 2025 | -$18.67 | +$4.76 |
| Q2 2025 | -$19.17 | -$0.88 |
| Q1 2025 | -$14.73 | +$2.69 |
| Q4 2024 | -$15.83 | +$0.22 |
AGL has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +5.9% |
| Q2 2026 | $1.5B | +7.2% |
| Q1 2026 | $1.4B | -7.3% |
| Q4 2025 | $1.6B | +3.1% |
| Q3 2025 | $1.4B | -1.1% |
| Q2 2025 | $1.4B | -5.9% |
| Q1 2025 | $1.5B | -4.5% |
| Q4 2024 | $1.5B | +87% |
AGL's revenue grew through 2024 and has held roughly level since: $1.5B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | +11 points |
| Q2 2026 | 0.8% | +9.1 points |
| Q1 2026 | 0.3% | +1.7 points |
| Q4 2025 | -12% | -5.3 points |
| Q3 2025 | -9.2% | 0 points |
| Q2 2025 | -8.3% | -5.4 points |
| Q1 2025 | -1.4% | -1 points |
| Q4 2024 | -7.1% | +13 points |
AGL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AGL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.6M | +$67.9M |
| Q2 2026 | -$60.7M | -$22.4M |
| Q1 2026 | $20.6M | +$56.5M |
| Q4 2025 | -$23.5M | -279% |
| Q3 2025 | -$21.3M | -$10.1M |
| Q2 2025 | -$38.3M | -$16.3M |
| Q1 2025 | -$35.8M | +$15.1M |
| Q4 2024 | $13.2M | +$78.3M |
AGL has burned cash in almost every quarter: −$17M over the past year, against −$82M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AGL on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +475K shares |
| 1 year | +6.7% | +1.1M shares |
| 3 years | +9% | +1.5M shares |
| 5 years | +13% | +2M shares |
| Available history | +15% | +2.3M shares |
AGL has 18M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q3 2020 | $6.7M |
| Q2 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AGL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AGL Net Leverage
AGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.8 | Neutral |
| Stochastic | 58.3 | Neutral |
AGL's weekly RSI is 64 (neutral) and its Stochastic is 58 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AGL PE vs Healthcare Sector
AGL has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.3 | 21% above |
| 20 week MA | $96.3 | 15% above |
| 50 week MA | $61.7 | 79% above |
| 100 week MA | $59.8 | 85% above |
| 200 week MA | $181.6 | 39% below |
AGL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $750.0 | $684.8 | -8.7% |
| 2022 | $684.8 | $407.0 | -41% |
| 2023 | $407.0 | $313.8 | -23% |
| 2024 | $313.8 | $47.5 | -85% |
| 2025 | $47.5 | $18.2 | -62% |
| 2026 YTD | $18.2 | $110.3 | +508% |
AGL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.